Pró-fármaco ativado por enzima, uma estratégia promissora na quimioterapia
Carregando...
Data
2006-11-01
Autores
Blau, Lorena [UNESP]
Menegon, Renato Farina [UNESP]
Chin, Chung Man [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Strategies that promote selective activation of prodrugs by enzymes can be divided into two major classes: 1) deliver of a monoclonal antibody-enzyme immunoconjugate that can recognize a specific antigen and promote the prodrug to a citotoxic drug, with a high selectivity for the target cells, and 2) selective gene delivery encoding an enzyme that can promote the prodrug to a citotoxic drug for the target cells. In this article are discussed ADEPT (antibody-directed enzyme prodrug therapy), GDEPT (gene-directed enzyme prodrug therapy), VDEPT (virus-directed enzyme prodrug therapy), GPAT (genetic prodrug activation therapy) and PDEPT (polymer-directed enzyme prodrug therapy) approaches, their clinical trials, advantages, disadvantages and perspectives.
Descrição
Palavras-chave
Cancer, Enzymes, Prodrugs
Como citar
Quimica Nova, v. 29, n. 6, p. 1307-1316, 2006.